Date: 2017-03-13
Type of information: Nomination
Compound:
Company: GlycoMimetics (USA - Md)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: • On March 13, 2017, GlycoMimetics announced the appointment of Scott Koenig to its Board of Directors. Dr. Koenig is President and Chief Executive Officer and a member of the Board of Directors of MacroGenics, a company specializing in antibody-based therapies for cancers and other diseases. He also serves as Chairman of the Board of the Applied Genetic Technologies Corporation. Dr. Koenig has been President, CEO and a director of MacroGenics since 2001 and was one of the company's founders. Previously, he was Senior Vice President of Research at MedImmune, participating in the selection and maturation of the company's product pipeline. Before that, he worked in the National Institute of Allergy and Infectious Diseases' Laboratory of Immunoregulation. In addition to serving as Chair of the Applied Genetic Technologies Corporation, he also serves as a member of the Board of Directors of the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance, and co-chairs the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Previously, he served as a member of the Scientific Management Review Board at the NIH, and of the Board of Directors of Children's National Health System, where he was also the Chairman of the Board of the Children's Research Institute. He received his M.D. from the University of Texas Health Science Center in Houston, and his Ph.D. and A.B. from Cornell University. In addition to the appointment of Dr. Koenig, GlycoMimetics also announced that two of its long-standing Board members would be stepping down. Franklin Top, Jr., M.D., will not be running for re-election when his term expires after the Company's upcoming Annual Meeting. John J. Baldwin, Ph.D., has also notified the Board of his intention to resign, effective after the GlycoMimetics Annual Meeting.
Financial terms:
Latest news:
